DUBLIN, March 7 (Reuters) - Shares in Irish drug maker Elan Corp. (ELN.I: Quote, Profile, Research) jumped as much as 10 percent on Tuesday before being suspended ahead of a crucial U.S. regulatory meeting later in the day for which analysts predicted a positive outcome. A panel of experts is due to meet over the next two days to decide whether to recommend the resumption of sales of Elan’s (ELN.L: Quote, Profile, Research) suspended multiple sclerosis drug Tysabri, developed with U.S. partner Biogen Idec (BIIB.O: Quote, Profile, Research).
